Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Evolus, Inc. - Common Stock (NQ:EOLS)

9.280 -0.020 (-0.22%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Evolus, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022
Upgrades 
Via Benzinga
Recap: Evolus Q4 Earnings
Evolus (NASDAQ:EOLS) reported its Q4 earnings results on Thursday, March 3, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Evolus missed... 
Via Benzinga
A Preview Of Evolus's Earnings
Evolus (NASDAQ:EOLS) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement. Analysts estimate... 
Via Benzinga
Evolus's Return On Capital Employed Overview
According to data from Benzinga Pro, during Q1, Evolus's (NASDAQ:EOLS) reported sales totaled $33.91 million. Despite a 3.72% increase in earnings, the company posted a loss of $17.50 million. 
Via Benzinga
Peer-Reviewed Post Hoc Analysis Shows Jeuveau® is Highly Effective for Millennials by All Measures and at All Time Points Assessed
From Evolus
Via Business Wire
Evolus Celebrates Third Anniversary of the Launch of Jeuveau® in the United States
From Evolus
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 13, 2022
Upgrades 
Via Benzinga
Evolus to Participate in the H.C. Wainwright Global Investment Conference
From Evolus
Via Business Wire
Evolus: Q1 Earnings Insights
Evolus (NASDAQ:EOLS) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Evolus beat estimated earnings by 6.06%,... 
Via Benzinga
Evolus Reports First Quarter 2022 Results and Provides Business Update
From Evolus
Via Business Wire
Evolus to Report First Quarter 2022 Results and Provide Business Update
From Evolus
Via Business Wire
Evolus Announces First Patient Enrolled in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau®
From Evolus
Via Business Wire
EVOLUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Evolus, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Evolus's Return On Capital Employed Insights
According to Benzinga Pro data, during Q4, Evolus (NASDAQ:EOLS) posted sales of $34.66 million. Earnings were up 6.46%, but Evolus still reported an overall loss of $18.18 million... 
Via Benzinga
Evolus Reports Narrower Q4 Loss, CFO Retires, Reaffirms FY22 Outlook
Evolus Inc's (NASDAQ: EOLS) Q4 FY21 sales increased 68% Y/Y to $34.7 million in line with interim results, beating the consensus of $33.99 million, driven... 
Via Benzinga
Earnings Scheduled For March 3, 2022
Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban... 
Via Benzinga
Evolus to Report Fourth Quarter and Year End 2021 Results and Provide Business Update
From Evolus
Via Business Wire
Evolus Receives Acceptance of Submission in Australia, a Pivotal Step in Approval Process for Nuceiva®
From Evolus
Via Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Nuvectis Pharma (NASDAQ:NVCT) stock moved upwards by 132.3% to $7.55 during Monday's regular session. The current volume of 17.0 million shares is 2307.5% of... 
Via Benzinga
Evolus to Participate in the Virtual 11th Annual SVB Leerink Global Healthcare Conference
From Evolus, Inc.
Via Business Wire
41 Biggest Movers From Yesterday
Gainers Ebang International Holdings Inc. (NASDAQ: EBON) shares gained 35.4% to settle at $1.09 on Wednesday as investors weighed the Federal Reserve Reserve decision to leave... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Rani Therapeutics Hldgs (NASDAQ:RANI 
Via Benzinga
Evolus Expects Q4 FY21 Sales Better Than Anticipated, Issues FY22 Guidance
Evolus Inc (NASDAQ: EOLS) has posted interim Q4 sales of approximately $34.7 million (better than the consensus of $30.87 million), up 68% Y/Y, driven by higher... 
Via Benzinga
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2021 Net Revenue and Provides 2022 Guidance
From Evolus, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 20, 2022
Upgrades For W.P. Carey Inc (NYSE:WPC), B... 
Via Benzinga
Evolus Expands Board of Directors With Appointment of Digital and Beauty Innovator Brady Stewart
From Evolus
Via Business Wire
Evolus Joins Nasdaq Biotechnology Index
From Evolus
Via Business Wire
Evolus Enters Into $125 Million Credit Facility with Pharmakon Advisors
From Evolus, Inc.
Via Business Wire
4 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Cara Therapeutics (NASDAQ:CARA) ... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback